Scarica l'app Stockscreener
60.76
0.28%
-0.17
Dopo l'orario di chiusura:
61.15
0.39
+0.64%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$60.93
Aprire:
$61.4
Volume 24 ore:
6.80M
Relative Volume:
0.60
Capitalizzazione di mercato:
$124.08B
Reddito:
$48.48B
Utile/perdita netta:
$7.27B
Rapporto P/E:
17.05
EPS:
3.5626
Flusso di cassa netto:
$11.91B
1 W Prestazione:
+3.47%
1M Prestazione:
+11.08%
6M Prestazione:
+10.59%
1 anno Prestazione:
+26.53%
Intervallo 1D:
$60.56
$61.70
Intervallo di 1 settimana:
$58.57
$62.29
Portata 52W:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.76 | 124.42B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,163.01 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.63 | 603.27B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
253.30 | 452.48B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
127.47 | 311.84B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.08 | 292.46B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-12-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
DOL Anchors Wave of Briefs Backing Bristol-Myers in PRT Appeal - plansponsor
DOL Takes Swipe At Derisking Cases In Bristol-Myers Brief - Law360
Bristol Myers Squibb stock stabilizes as Eliquis and Opdivo help offset Revlimid erosion - Ad-hoc-news.de
Donald TrumpBRISTOL MYERS SQUIBB CO Trump Trade on May. 18, 2026 - Quiver Quantitative
Bristol Myers Squibb stock steadies as Eliquis and Opdivo shape earnings outlook - Ad-hoc-news.de
Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued? - simplywall.st
Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating - The Motley Fool
Alexandria Real Estate Equities (ARE) Delivers 427,000 RSF Bristol Myers Squibb R And D Hub - Yahoo Finance
Bristol Myers Squibb stock edges higher as recent results and oncology portfolio shape investor view - Ad-hoc-news.de
Bristol Myers Squibb Partners With NVIDIA to Build Pharma's Largest Supercomputer - Mjengo Hub
Bristol Myers Squibb Supercharges Drug Discovery With NVIDIA AI - Sahm
Bristol Myers Squibb (BMY) Opens 427,000 Square Foot San Diego Hub For AI Drug Discovery - Yahoo Finance UK
Bristol Myers Squibb stock trades steadily as oncology and immunology portfolio supports earnings tr - Ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as oncology pipeline and recent earnings shape sentiment - Ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as oncology pipeline and Revlimid erosion shape outlook - Ad-hoc-news.de
BMS: Boosting AI Drug Discovery Capacity with NVIDIA Tech - Healthcare Digital
Bristol Myers Squibb Expands AI Infrastructure With NVIDIA to Build AI Factory for Drug Discovery - Digital Health News
Bristol Myers Squibb buys Nvidia AI system for drug discovery - AI News
Bristol Myers Squibb stock trades steady as oncology pipeline and recent results frame investor focu - Ad-hoc-news.de
Bristol Myers Squibb (BMY) Expands AI Capabilities with Nvidia S - GuruFocus
BMS claims pharma's most powerful AI supercomputer. How it stacks up to Lilly's and Roche's. - drugdiscoverytrends.com
Bristol Myers Squibb (BMY) Enhances AI Capabilities with New NVI - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Bristol Myers Squibb stock steadies as investors weigh Opdivo growth and pending Karuna Therapeutics - Ad-hoc-news.de
BMS expands NVIDIA tie-up with Vera Rubin AI factory - The Pharma Letter
Bristol Myers Squibb stock holds steady as Eliquis and Opdivo underpin earnings outlook - Ad-hoc-news.de
Bristol Myers Squibb, NVIDIA build AI factory for drug discovery - MobiHealthNews
Alexandria Delivers R&D Hub for Bristol Myers Squibb at San Diego Megacampus - Connect CRE
Bristol Myers Squibb Expands AI Drug Discovery With NVIDIA Vera Rubin SuperPOD - AIM Media House
Bristol Myers Squibb expands Nvidia partnership to supercharge its AI drug factory - Crypto Briefing
Bristol Myers buys Nvidia's latest AI computing system for drug research - Reuters
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory - Pharmaceutical Executive
BMS, Nvidia aim for ‘most powerful AI factory in life sciences’ - Fierce Biotech
BMS again turns to NVIDIA to ramp up AI compute for drug discovery - FirstWord Pharma
Alexandria delivers 427,000 sq ft R&D facility for Bristol Myers - Investing.com
Bristol Myers Squibb to build the most powerful AI factory in life sciences with NVIDIA - Chain Drug Review
Bristol Myers boosts AI capacity with expanded use of Nvidia systems - Seeking Alpha
Bristol Myers Squibb expands AI infrastructure with NVIDIA By Investing.com - Investing.com Nigeria
Nvidia partners with Bristol-Myers Squibb to build AI supercomputer for drug discovery - Crypto Briefing
Bristol Myers Squibb expands AI infrastructure with NVIDIA - Investing.com
Bristol Myers Squibb becomes latest company to claim it’s building pharma’s largest NVIDIA AI supercomputer - STAT
Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA - marketscreener.com
Bristol Myers Squibb stock trades steady as oncology focus meets mixed revenue trends - Ad-hoc-news.de
Bristol-Myers Squibb stock trades steady as Opdivo and Eliquis anchor earnings and pipeline focus - Ad-hoc-news.de
Bristol Myers Squibb stock trades steady as oncology and immunology portfolio underpins recent earni - Ad-hoc-news.de
Bristol Myers (BMY) Is Up 5.5% After FDA Accepts Mezigdomide NDA In Multiple Myeloma - simplywall.st
Bristol Myers Squibb stock trades steady as Revlimid erosion offsets Opdivo and Eliquis growth - ad-hoc-news.de
Bristol Myers Squibb Co (NYSE:BMY): A High Yield Dividend Stock Backed by Strong Profitability - ChartMill
Bristol Myers Squibb stock steadies as Opdivo and Eliquis underpin earnings power - ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as Eliquis and Opdivo drive earnings and cash flow - Ad-hoc-news.de
Bristol Myers Squibb stock trades steadily as cardiovascular and oncology portfolio supports earning - Ad-hoc-news.de
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):